Finanzen von Protagonist Therapeutics Inc (PTGX)PTGXProtagonist Therapeutics Inc

Evaluating the bottom line, Protagonist Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 74.37%, while the net margin is 76.28%. These profitability ratios, combined with a Return on Equity (ROE) of 10.98%, provide a clear picture of how effectively PTGX converts its operational activities into shareholder value.

In the context of the broader market, PTGX competes directly with industry leaders such as PRAX and CRNX. With a market capitalization of $10.04B, it holds a leading position in the sector. When comparing efficiency, PTGX's gross margin of 100.00% stands against PRAX's N/A and CRNX's 99.39%. Such benchmarking helps identify whether Protagonist Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Protagonist Therapeutics has shown significant revenue growth, with Q2 2026 revenue at $213.48 million, up from $5.00 million in Q1 2024. The company also reported a positive net income of $162.85 million in Q2 2026, a substantial turnaround from previous losses.